Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cantharidic_Acid SCHEMBL13091537 | 1.00 | MAPK1 (1.00) | MAPK1TP53LMNAHIF1ANPC1 | |
| Cantharidic_Acid SCHEMBL24226002 | 1.00 | MAPK1 (1.00) | MAPK1TP53LMNAHIF1ANPC1 | |
| SCHEMBL16542813 | 0.91 | MAPK1 (0.83) | MAPK1TP53LMNAHIF1ANPC1 | |
| SCHEMBL3494225 | 0.88 | MAPK1 (0.77) | MAPK1TP53LMNAHIF1ANPC1 | |
| SCHEMBL20885049 | 0.83 | MAPK1 (0.70) | MAPK1TP53LMNAHIF1ANPC1 | |
| SCHEMBL14398404 | 0.82 | MAPK1 (0.67) | MAPK1TP53LMNAHIF1ANPC1 | |
| SCHEMBL27616131 | 0.78 | MAPK1 (0.61) | MAPK1TP53LMNAHIF1ANPC1 | |
| SCHEMBL20885003 | 0.76 | MAPK1 (0.59) | MAPK1TP53LMNAHIF1ANPC1 | |
| Cantharidic_Acid SCHEMBL29360065 | 0.76 | MAPK1 (0.61) | MAPK1TP53LMNAHIF1ANPC1 | |
| SCHEMBL28493026 | 0.69 | MAPK1 (0.52) | MAPK1TP53LMNAHIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302794-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | VERRICA PHARMACEUTICALS INC. (US) | 2025-10-02 | — | — | US | claimed |
| WO-2025125890-A1 | PROTEIN PHOSPHATASE 2A (PPA2) ANTAGONISTS FOR DENGUE TREATMENT | CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL I.P.N. (MX) | 2025-06-19 | — | — | WO | claimed |
| CN-117717564-A | Application of antisense oligonucleotide in preparing medicine for treating lung cancer | 北京悦康科创医药科技股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-20110002877-A1 | PTEN Inhibitors Treat Neutropenia-Associated Pneumonia | CHILDREN'S MEDICAL CENTER CORPORATION | 2011-01-06 | — | — | US | claimed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | Cartesian Therapeutics Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | ENTERIN, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CARTESIAN THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250302794-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | VERRICA PHARMACEUTICALS INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-2502623-A1 | Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation | Children's Medical Center Corporation (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2282738-A2 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | Children's Medical Center Corporation (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110002877-A1 | PTEN Inhibitors Treat Neutropenia-Associated Pneumonia | CHILDREN'S MEDICAL CENTER CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20090305333-A1 | Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | disclosed |
| WO-2009149435-A2 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20070203098-A1 | Pten Inhibitors | SEMAFORE PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203098-A1 | Pten Inhibitors | SEMAFORE PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203098-A1 | Pten Inhibitors | SEMAFORE PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MAPK1 4534/4885TP53 75/4885LMNA 4710/4885 |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | TFAM, FIS1, TUFM | MAPK1 2596/4885TP53 723/4885LMNA 1828/4885 |
| US-20110002877-A1 | PTEN Inhibitors Treat Neutropenia-Associated Pneumonia | CSF3R, CSF1R, ATM | MAPK1 377/4885TP53 6/4885LMNA 3952/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | MAPK1 1689/4885TP53 162/4885LMNA 1373/4885 |
| US-20070203098-A1 | Pten Inhibitors | PTEN, MTMR1, PTPRJ | MAPK1 746/4885TP53 53/4885LMNA 2778/4885 |
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | HLA-C, CPA3, HLA-A | MAPK1 3909/4885TP53 1077/4885LMNA 3998/4885 |
| US-20250302794-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | CUTA, NISCH, WARS1 | MAPK1 3907/4885TP53 190/4885LMNA 3218/4885 |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | HSD3B1, HSD3B2, HSD11B1 | MAPK1 3476/4885TP53 3828/4885LMNA 996/4885 |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CD74, CCR1, MSR1 | MAPK1 2421/4885TP53 504/4885LMNA 4530/4885 |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | CYP17A1, HSD17B13, HSD17B7 | MAPK1 4413/4885TP53 3585/4885LMNA 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.